| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.01. | Daxor schließt Kapitalerhöhung über 8,1 Mio. US-Dollar an der NASDAQ ab | 1 | Investing.com Deutsch | ||
| 23.01. | Daxor Corporation Announces $9 Million Registered Direct Offering | 1 | GlobeNewswire (USA) | ||
| 23.01. | DAXOR CORP - 8-K, Current Report | 2 | SEC Filings | ||
| 21.10.25 | Daxor Corporation: Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit | 2 | GlobeNewswire (USA) | ||
| 30.09.25 | Daxor Corporation: Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA | 272 | GlobeNewswire (Europe) | Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation... ► Artikel lesen | |
| DAXOR Aktie jetzt für 0€ handeln | |||||
| 23.09.25 | Daxor stellt auf Fachtagung neues, von der FDA zugelassenes Blutanalysegerät vor | 4 | Investing.com Deutsch | ||
| 23.09.25 | Daxor to showcase new FDA-cleared blood volume analyzer at HFSA meeting | 1 | Investing.com | ||
| 23.09.25 | Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting | 3 | GlobeNewswire (USA) | ||
| 07.08.25 | Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System | 220 | GlobeNewswire (Europe) | Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume... ► Artikel lesen | |
| 04.03.25 | Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 | 219 | GlobeNewswire (Europe) | Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the... ► Artikel lesen | |
| 04.03.25 | Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 | 219 | GlobeNewswire (Europe) | Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,370 | -2,41 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| THERMO FISHER | 434,95 | -1,37 % | THERMO FISHER SCIENTIFIC INC. - 10-K, Annual Report | ||
| SERNOVA BIOTHERAPEUTICS | 0,081 | -5,85 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Warrant Amendments | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company... ► Artikel lesen | |
| FAMICORD | 5,100 | -1,92 % | EQS-News: FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung | EQS-News: FamiCord AG
/ Schlagwort(e): 9-Monatszahlen
FamiCord AG beschleunigt profitables Wachstum im dritten Quartal 2025 und stärkt Qualität und Visibilität der Umsatzentwicklung... ► Artikel lesen | |
| INNOVAQOR | - | - | InnovaQor, Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| PLUS THERAPEUTICS | 0,302 | -0,17 % | Plus Therapeutics Inc.: Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ | HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MEDICLIN | 3,900 | +1,04 % | EQS-PVR: MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MEDICLIN AG
MEDICLIN AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.02.2026 / 10:41 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA 7300,B0Y,YAG: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZEROSTACK CORP.... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results | Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior yearNet loss and net loss per share decreased from prior year for... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| CO-DIAGNOSTICS | 0,172 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.01.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 22.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.01.2026ISIN NameCA74290F1009 PROBE... ► Artikel lesen | |
| QUIDELORTHO | 19,100 | -1,04 % | QuidelOrtho Corporation: QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio | Agreement adds new analyzer platforms and expands assay menu across key international marketsSAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply... ► Artikel lesen | |
| VERU | 2,620 | +2,34 % | Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress | -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast... ► Artikel lesen |